Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

[Combination of transrectal 125I seeds implantation brachytherapy and intermittent hormonal therapy for locally advanced prostate cancer].

Wu HM, Lü J, Hu WL, Zhang JH, Wang W, Xiao YS, Wang NX, Ran JW, Huang XD.

Zhonghua Nan Ke Xue. 2013 Jul;19(7):617-21. Chinese.

PMID:
23926678
[PubMed - indexed for MEDLINE]
2.

Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds.

Sugawara A, Nakashima J, Kunieda E, Nagata H, Asakura H, Oya M, Shigematsu N.

Radiat Oncol. 2010 Sep 28;5:86. doi: 10.1186/1748-717X-5-86.

PMID:
20875137
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

[Impact of neoadjuvant hormonal therapy on the permanent ¹²⁵I-seed brachytherapy for localized high-risk prostate cancer].

Zhuang HY, Xu XM, Peng T, Lin CP.

Zhonghua Yi Xue Za Zhi. 2010 Dec 28;90(48):3418-20. Chinese.

PMID:
21223817
[PubMed - indexed for MEDLINE]
4.

Prostate brachytherapy: treatment strategies.

Stone NN, Stock RG.

J Urol. 1999 Aug;162(2):421-6.

PMID:
10411050
[PubMed - indexed for MEDLINE]
5.

[Application of neoadjuvant hormonal therapy in (125)I permanent seed implantation for prostate cancer].

Cui X, Li Q, Xu JJ, Li J, Ou TW.

Zhonghua Yi Xue Za Zhi. 2012 Oct 16;92(38):2710-2. Chinese.

PMID:
23290112
[PubMed - indexed for MEDLINE]
6.

Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.

Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger PD.

Cancer. 1996 Jun 1;77(11):2386-92.

PMID:
8635111
[PubMed - indexed for MEDLINE]
7.

Brachytherapy with transperineal (125)Iodine seeds for localized prostate cancer.

Blank LE, Gonzalez Gonzalez D, de Reijke TM, Dabhoiwala NF, Koedooder K.

Radiother Oncol. 2000 Dec;57(3):307-13.

PMID:
11104891
[PubMed - indexed for MEDLINE]
8.

Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.

Lehrer S, Cesaretti J, Stone NN, Stock RG.

BJU Int. 2006 Nov;98(5):979-81.

PMID:
17034599
[PubMed - indexed for MEDLINE]
9.

Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.

Borchers H, Kirschner-Hermanns R, Brehmer B, Tietze L, Reineke T, Pinkawa M, Eble MJ, Jakse G.

BJU Int. 2004 Oct;94(6):805-11.

PMID:
15476513
[PubMed - indexed for MEDLINE]
10.

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.

Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA.

J Clin Oncol. 1999 Feb;17(2):517-22.

PMID:
10080594
[PubMed - indexed for MEDLINE]
11.

Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.

Tanaka N, Fujimoto K, Hirao Y, Asakawa I, Hasegawa M, Konishi N.

Urology. 2009 Aug;74(2):407-11. doi: 10.1016/j.urology.2008.12.062. Epub 2009 Apr 18.

PMID:
19376570
[PubMed - indexed for MEDLINE]
12.

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.

Merrick GS, Butler WM, Galbreath RW, Lief JH.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):41-8.

PMID:
11516849
[PubMed - indexed for MEDLINE]
13.

(125)Iodine prostate brachytherapy: outcome from the first 100 consecutive patients and selection strategies incorporating urodynamics.

Henderson A, Cahill D, Laing RW, Langley SE.

BJU Int. 2002 Oct;90(6):567-72.

PMID:
12230619
[PubMed - indexed for MEDLINE]
14.

[Brachytherapy of 125I implantation for localized prostate cancer (report of 41 cases)].

Bai Q, Wang Y, Kaye KW.

Zhonghua Nan Ke Xue. 2004 May;10(5):371-3. Chinese.

PMID:
15190833
[PubMed - indexed for MEDLINE]
15.

Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.

Miller N, Smolkin ME, Bissonette E, Theodorescu D.

Cancer. 2005 Jun 15;103(12):2499-506.

PMID:
15852361
[PubMed - indexed for MEDLINE]
Free Article
16.

Urinary symptom flare following I-125 prostate brachytherapy.

Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1085-92.

PMID:
12829146
[PubMed - indexed for MEDLINE]
17.

The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.

Niehaus A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E.

Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):136-43. Epub 2005 Sep 28.

PMID:
16198062
[PubMed - indexed for MEDLINE]
18.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
[PubMed - indexed for MEDLINE]
19.

The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy.

Crook J, Toi A, McLean M, Pond G.

Brachytherapy. 2002;1(3):131-7.

PMID:
15090275
[PubMed - indexed for MEDLINE]
20.

A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.

Kollmeier MA, Pei X, Algur E, Yamada Y, Cox BW, Cohen GN, Zaider M, Zelefsky MJ.

Brachytherapy. 2012 Jul-Aug;11(4):271-6. doi: 10.1016/j.brachy.2011.11.002. Epub 2011 Dec 20.

PMID:
22192495
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk